☰

Angela D. Pardee, Ph.D. - Publications

Affiliations: 
2010 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Immunology, Oncology
Tree Info Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH. Tumor-derived α-fetoprotein directly drives human natural killer cell activation and subsequent cell death. Cancer Immunology Research. PMID 28468916 DOI: 10.1158/2326-6066.Cir-16-0216  0.716
2015 Pardee AD, Yano H, Weinstein AM, Ponce AA, Ethridge AD, Normolle DP, Vujanovic L, Mizejewski GJ, Watkins SC, Butterfield LH. Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. Journal For Immunotherapy of Cancer. 3: 32. PMID 26199728 DOI: 10.1186/S40425-015-0077-X  0.695
2015 Vujanovic L, Stahl E, Pardee A, Watkins S, Gibson G, Butterfield LH. Tumor-derived alpha fetoprotein directly impacts human natural killer cell activity and viability Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P289  0.739
2015 Santos PM, Pardee A, Delgoffe GM, Butterfield LH. Tumor-derived alpha-fetoprotein (tAFP) causes immune and metabolic dysfunction in monocyte-derived dendritic cells Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P210  0.469
2014 Pardee AD, Shi J, Butterfield LH. Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 193: 5723-32. PMID 25355916 DOI: 10.4049/Jimmunol.1400725  0.59
2014 Pardee AD, Shi J, Butterfield LH. Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells Journal For Immunotherapy of Cancer. 2: 229. DOI: 10.1186/2051-1426-2-S3-P229  0.586
2012 Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology. 1: 287-357. PMID 22737604 DOI: 10.4161/Onci.18628  0.729
2012 Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology. 1: 48-55. PMID 22720211 DOI: 10.4161/Onci.1.1.18344  0.418
2010 Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Research. 70: 9041-52. PMID 21045144 DOI: 10.1158/0008-5472.Can-10-1369  0.676
2010 Qu Y, Chen L, Pardee AD, Taylor JL, Wesa AK, Storkus WJ. Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 185: 2895-902. PMID 20675595 DOI: 10.4049/Jimmunol.1001294  0.699
2010 Pardee AD, Epstein AL, Storkus WJ. Abstract 2938: A novel OX40 agonist licenses systemic anti-tumor immunity to overcome local immune suppression induced by well-established tumors Cancer Research. 70: 2938-2938. DOI: 10.1158/1538-7445.Am10-2938  0.7
2009 Pardee AD, Wesa AK, Storkus WJ. Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy. 1: 249-64. PMID 20046961 DOI: 10.2217/1750743X.1.2.249  0.606
2009 Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 793-802. PMID 19752754 DOI: 10.1097/Cji.0B013E3181Acec1E  0.662
2008 Sasaki K, Pardee AD, Okada H, Storkus WJ. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. European Journal of Immunology. 38: 2865-73. PMID 18958887 DOI: 10.1002/Eji.200838334  0.629
2008 Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, Alber S, Watkins SC, Pardee AD, Wesa AK, Storkus WJ. CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Research. 68: 8076-84. PMID 18829566 DOI: 10.1158/0008-5472.Can-08-0387  0.642
2008 Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. Journal of Immunology (Baltimore, Md. : 1950). 181: 104-8. PMID 18566374 DOI: 10.4049/Jimmunol.181.1.104  0.664
Show low-probability matches.